- Home
- SOHU vs SCTX Comparison
SOHU vs SCTX Comparison
Compare SOHU & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOHU | SCTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 330.1M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SOHU | SCTX |
|---|---|---|
| Price | $14.28 | $34.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 45.0K | ★ 222.5K |
| Earning Date | 05-18-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $17.31 |
| 52 Week High | $17.30 | $39.60 |
Technical Indicators
Market Signals| Indicator | SOHU | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 73.79 |
| Support Level | $12.97 | $19.09 |
| Resistance Level | $14.83 | N/A |
| Average True Range (ATR) | 0.65 | 3.51 |
| MACD | 0.01 | 1.28 |
| Stochastic Oscillator | 47.14 | 75.48 |
Price Performance
Historical ComparisonAbout SOHU Sohu.com Limited
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.